Immuron Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IMRN | AIM | IMM.L | IMUX | IMNN | ET80.F | |
|---|---|---|---|---|---|---|
| Market cap | 6.88M | 6.42M | 20.16M | 108.34M | 5.09M | 5.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -85.3 | -0.4 | 0.0 | -3.4 | -0.5 | — |
| Price/book | 0.9 | 0.6 | 10.7 | 0.8 | 2.2 | 0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −43.05% | −90.12% | −67.26% | +5.12% | −77.02% | −12.33% |
| Today | −0.84% | +0.19% | −0.96% | +4.47% | +0.78% | +0.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IMRN news ›Immuron Reports Phase 2 Travelan Results Published In Scientific Reports; Stock Down
Immuron Limited (IMRN) announced that results from its Phase 2 clinical trial evaluating once-daily oral Travelan have been published in the journal Scientific Reports, providing further insight into the product's potential role in…
More from 1 other outlet
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th…
Immuron proposes up to 10% extra share-issue capacity
Cash issues under the proposed placement facility must be priced at not less than 75% of VWAP. If shareholders approve Resolution 3, Immuron gains authority—not an issuance—to sell ordinary shares for cash at no less than 75% of the VWAP…
Accelerating Enrollment For Direct-To-Patient Observational Studies: A Case Study In Traveler's Diarrhea
Accelerating Enrollment For Direct-To-Patient Observational Studies A Case Study In Travelers Diarrhea Med Device Online Accelerating Enrollment For Direct-To-Patient Observational Studies: A Case Study In Traveler's Diarrhea Enrolling a…
Phase 3 MOTION Trial Efficacy and Safety
The faculty review the phase 3 MOTION trial of vimseltinib in TGCT, describing the results as robust. CSF1 inhibitors are described as shrinking tumors and addressing the inflammatory component of the disease, with a waterfall plot showing…
Immuron Travelan Phase 2 misses primary efficacy goals
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2026 Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark…
Phase 2 trial shows Travelan cuts travelers' diarrhea severity by up to 50%, published in Nature Journal.
Immuron Limited published Phase 2 trial results for Travelan, an oral immunotherapy for travelers' diarrhea, in the Nature Journal. The study showed Travelan significantly reduced diarrhea severity and early antibiotic use by up to 71%,…
Travelan® Phase 2 Study Results Published
October 13, 2026 06:00 ET | Source: Immuron Limited Immuron Limited MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- kalkinemedia.com1
- manilatimes.net1
- pluang.com1
- rttnews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.